Fleming Laboratories

What Fleming Laboratories does

Fleming Laboratories Limited is a Hyderabad-based, privately held manufacturer of generic Active Pharmaceutical Ingredients (APIs) supplying global pharmaceutical companies across the EU, US, Japan, Korea, China, Russia, Brazil, Mexico, Canada and Taiwan. Founded in 1995 and operating as Fleming Laboratories Limited under Telangana jurisdiction, the company runs four manufacturing facilities plus a DSIR-accredited R&D centre: Unit I at Nawabpet, Telangana (48,000 sq. mt, 190 KL reactor capacity, 220 employees); Unit II at Jeedimetla, Hyderabad (2,100 sq. mt, 8 KL capacity, 60 employees); Unit III at Yadagir, Karnataka, commissioned December 2023 through wholly-owned subsidiary Fleming Lifesciences Private Limited (42,000 sq. mt, phase 1 capacity 6 KL, 50 employees); and Unit IV, a fermentation facility at Medak District commissioned March 2024 through a joint venture with Fermac Bio Pvt Ltd (20,000 sq. mt, 200 KL phase 1 capacity, 64 employees). Total headcount across manufacturing units is 394, supported by an 18-member R&D team.

The company produces 24 documented generic APIs spanning antihistamines (Buclizine HCl, Cinnarizine, Cyproheptadine HCl, Meclizine HCl, Flunarizine HCl, Hydroxyzine HCl, Ketotifen Fumarate), muscle relaxants and pain management (Carisoprodol, Etodolac, Etofenamate, Pentoxifylline), anti-diarrheals (Loperamide HCl), prostaglandins (Bimatoprost, Travoprost, Misoprostol Dispersion), cardiovascular (Diltiazem HCl), anesthetics (Prilocaine, Propofol), epilepsy (Topiramate), osteoporosis (Ibandronate Sodium, Risedronate Sodium), Wilson's disease (D-Penicillamine), and anti-muscarinics (Tolterodine Tartrate, Trospium Chloride). Core technical capabilities include complex chemistry process development, impurity profiling (including genotoxic and nitrosamine assessment), synthesis, characterization, regulatory query resolution, and integrated tech transfer with EHS risk assessment. Each product is documented under pharmacopoeia grades (EP, USP, BP, IP) and supported by eCTD DMF, CEP, ASMF, KDMF, JDMF and CADIFA filings.

Fleming operates a B2B direct sales model, generating revenue through negotiated per-product, per-volume sales of manufactured APIs to pharmaceutical customers via its in-house business development and marketing team, with regulatory and quality teams supporting enterprise engagements. The company holds regulatory approvals from 14+ agencies including EU GMP, WHO GMP, PMDA Japan, US FDA, COFEPRIS Mexico, KFDA Korea, ANVISA Brazil, NMPA China, EDQM, MOH Taiwan/Russia, Malta, Portugal, Israel and Health Canada—a profile that materially lowers regulatory friction for global customers. In December 2023, the company raised growth capital from InvAscent and is currently executing a multi-site capacity expansion including new manufacturing units and fermentation capabilities through the Fermac Bio JV.

Name

Fleming Laboratories

Legal name

Fleming Laboratories Limited

Website

https://fleminglabs.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

251–500 employees

Short description

Fleming Laboratories Limited is a Hyderabad-based manufacturer of generic Active Pharmaceutical Ingredients supplying global pharmaceutical companies. It operates four manufacturing facilities and an R&D centre, producing 24+ APIs across multiple therapeutic categories with multi-jurisdictional regulatory approvals.

Ownership category

akta.pro rank

Product category

Generic Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Generic API manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• API regulatory filings
• Pharmaceutical intermediates supply

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Product Sales: Revenue generated from the manufacture and supply of generic Active Pharmaceutical Ingredients (APIs) to the global pharmaceutical industry. The company supplies APIs across therapeutic categories including antihistamines, muscle relaxants, anti-diarrheals, prostaglandins, cardiovascular, anesthetics, and treatments for osteoporosis and Wilson's disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Fleming Laboratories Limited manufactures and supplies high-quality generic Active Pharmaceutical Ingredients (APIs) to the global pharmaceutical industry across multiple therapeutic categories. The company operates four manufacturing units in India (Nawabpet, Jeedimetla, Yadgir/Karnataka, and Medak District via the Fermac Bio JV) and a DSIR-accredited R&D centre in Hyderabad, producing 24 distinct APIs with regulatory filings in EU GMP, WHO GMP, PMDA, US FDA, KFDA, NMPA, ANVISA, COFEPRIS, and EDQM CEP formats for pharmaceutical formulation customers.

Product overview

Fleming Laboratories Limited is a manufacturer and supplier of high-quality generic Active Pharmaceutical Ingredients (APIs) to the global pharmaceutical industry. The company's product portfolio comprises 24 distinct generic APIs organized across two manufacturing units: Unit I (Nawabpet, Telangana) produces 18 APIs spanning anti-histamine/anti-cholinergic, muscle relaxant/pain management, anti-diarrheal, prostaglandins, cardiovascular, anesthetic, and epilepsy therapeutic categories; Unit II (Jeedimetla, Hyderabad) produces 6 APIs covering anti-histamine, Wilson's disease, osteoporosis, and anti-muscarinic treatments. The products range from documented formulations with full regulatory filings (eCTD DMF, CEP, ASMF) to technical pack-only offerings, serving different market requirements across global regulatory jurisdictions.

Differentiator

Problem solved

Functional benefit

Products and services

• Buclizine HCl Anti-histamine/anti-cholinergic generic API manufactured at Unit I (Nawabpet), documented under BP grade with eCTD DMF and ASMF regulatory formats for pharmaceutical formulation customers.
• Cinnarizine Anti-histamine generic API available in EP, BP, and IP grades with eCTD DMF and CEP documentation for pharmaceutical formulation customers.
• Cyproheptadine HCl Anti-histamine generic API in EP, BP, USP, and IP grades with eCTD DMF documentation.
• Meclizine HCl Anti-histamine generic API documented under EP, BP, and USP grades with eCTD DMF, JDMF, CEP, and CADIFA documentation for global markets.
• Flunarizine HCl Anti-histamine generic API in EP and BP grades with eCTD DMF and CEP documentation.
• Hydroxyzine HCl Anti-histamine generic API available in USP, EP, and IP grades with eCTD DMF, CEP, and US DMF documentation.
• Carisoprodol Muscle relaxant generic API in EP, USP, and IP grades with eCTD DMF documentation.
• Etodolac Muscle relaxant/pain management generic API in EP, USP, and IP grades with eCTD DMF and CEP documentation.
• Etofenamate Muscle relaxant/pain management generic API in EP grade supplied with technical pack only.
• Pentoxifylline Muscle relaxant/pain management generic API in EP and USP grades with eCTD DMF documentation.
• Loperamide HCl Anti-diarrheal generic API in EP, BP, and USP grades with eCTD DMF and CEP documentation.
• Bimatoprost Prostaglandin generic API in in-house and USP draft grades with eCTD DMF documentation.
• Travoprost Prostaglandin generic API in USP grade supplied with technical pack only.
• Misoprostol Dispersion Prostaglandin generic API in USP grade with eCTD DMF documentation under GMP and WHO GMP compliance.
• Diltiazem HCl Cardiovascular generic API in EP, USP, and IP grades with eCTD DMF and CEP documentation.
• Prilocaine Anesthetic generic API in EP grade with eCTD DMF documentation under GMP compliance.
• Propofol Anesthetic generic API in USP and EP grades supplied with technical pack only.
• Topiramate Epilepsy generic API in USP and EP grades with eCTD DMF documentation under WHO GMP and EU-WC compliance.
• Ketotifen Fumarate Anti-histamine generic API manufactured at Unit II (Jeedimetla) in EP, IP, and USP grades with eCTD DMF, ASMF, and KDMF documentation.
• D-Penicillamine Wilson's disease treatment generic API in IP, USP, and EP grades with eCTD DMF, CEP, and ASMF documentation.
• Ibandronate Sodium Monohydrate Osteoporosis treatment generic API in in-house, EP, and USP grades with eCTD DMF, KDMF, and CEP documentation.
• Risedronate Sodium (HH/AH) Osteoporosis treatment generic API in EP, USP, IP, and in-house grades with eCTD DMF, KDMF, and CEP documentation.
• Tolterodine Tartrate Anti-muscarinic generic API in USP, in-house, and EP grades with eCTD DMF and CEP documentation.
• Trospium Chloride Anti-muscarinic generic API in EP, USP, and IP grades with eCTD DMF and CEP documentation.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Divis Laboratories: One of India's largest independent API manufacturers with a similarly broad small-molecule portfolio and global regulatory dossier. Divis is a directly comparable Indian API pure-play, though meaningfully larger in scale and publicly listed.
• Laurus Labs: Indian API and CDMO manufacturer with multi-jurisdictional regulatory approvals supplying global generic and innovator pharma. Direct peer given the overlapping API product range, fermentation/synthesis mix, and B2B go-to-market to global customers.
• Aurobindo Pharma: Large vertically integrated Indian generic manufacturer with a significant API business supplying both internal and external customers. A directly comparable peer in scale of regulatory footprint and therapeutic breadth, though with a much larger formulation business alongside.
• MSN Laboratories: Indian API and finished-dose manufacturer with deep regulatory filings across EU, US, and emerging markets. Direct peer — comparable mid-sized Indian generic API supplier serving similar global generic customers with overlapping therapeutic categories.
• Hetero Drugs: Large Indian API and formulations manufacturer supplying ARV, antihistamine, and other generic categories globally. A directly comparable peer given the overlapping generic API portfolio and multi-region regulatory dossier strategy.
• Aarti Drugs: Mid-sized Indian API manufacturer focused on generic small molecules across multiple therapeutic areas with global customer reach. Closely comparable to Fleming in scale, business model, and portfolio composition.
• Neuland Laboratories: Indian API manufacturer and CDMO serving global generic and innovator pharma with US FDA, EDQM, and other regulatory filings. Direct peer given the small-molecule API focus, US/EU customer base, and similar B2B supply model.
• Solara Active Pharma Sciences: Indian API manufacturer supplying global generic customers with a portfolio of generic small molecules and established multi-jurisdictional regulatory filings. Closely comparable to Fleming in scale, therapeutic mix, and go-to-market approach.
• Granules India: Indian API and finished-formulation manufacturer with global regulatory approvals supplying generic pharma companies. Direct peer — comparable API manufacturing platform and customer base, with a parallel formulation business.

Emerging players

• Sai Life Sciences: Indian API and CRO/CDMO player with growing fermentation and complex chemistry capabilities. Partially comparable — overlapping on the API manufacturing and process R&D side, but with a stronger CRO/CDMO tilt and less of a pure-generic API focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fleming Laboratories